Health China

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Contribution of the UPR and HDMX to the Development of TKI Resistance DF/HCC SPORE in Kidney Cancer January, 2012
2. The Emerging Role of p53 in TKI Resistance Kidney Cancer Association, Chicago, IL January, 2012
3. HDM2 as a Therapeutic Target in Melanoma and Renal Cell Carcinoma Cancer Biology Program, BethIsraelDeaconessMedicalCenter January, 2011
4. HDM2 as a Therapeutic Target in Renal Cell Carcinoma Roswell Park Cancer Institute, Buffalo, NY January, 2011
5. HDM2 as a Therapeutic Target in Melanoma DF/BWCC Melanoma Lecture Series January, 2011
6. HDM2 as a Therapeutic Target in Melanoma and Renal Cell Carcinoma Sanofi-Aventis, Cambridge, MA January, 2011
7. Mechanism of Acquired Resistance to VEGF Receptor Antagonists Neuro-Oncology Program, Brigham and Women’s Hospital January, 2010
8. Mechanisms of Acquired Resistance to VEGF Receptor Antagonists Genitourinary Cancers Symposium (GU ASCO), Orlando, FL January, 2009
9. Mechanism of Acquired Resistance to VEGF Receptor Antagonists Kidney Cancer Program/SPORE Scientific Retreat January, 2009
10. Modulation of Response to BRAF Inhibition by GSK-3 ArQule, Inc., Woburn, MA January, 2009
11. VEGF-R TKI Resistance Mechanisms and Therapy Innovations and Challenges in Renal Cancer, Third Cambridge Conference, Cambridge, MA January, 2008
12. Mechanism of Acquired Resistance to VEGF Receptor Antagonists DF/HCC GU Oncology seminar series January, 2008
13. Mechanism of Acquired Resistance to VEGF Receptor Antagonists Department of Experimental Pathology, BethIsraelDeaconessMedicalCenter January, 2007
14. Therapy of Metastatic Renal Cell Carcinoma Division of Oncology, MaineMedicalCenter, Portland, ME January, 2007
15. Differential Susceptibility of Melanoma Cells to Sorafenib-Induced Apoptosis Department of Experimental Therapeutics, MD AndersonHospital, Houston, TX January, 2006
16. Mechanism of Sorafenib-Induced Apoptosis in Melanoma Cells Chiron, Inc., Emeryville, CA January, 2005
17. Mechanism of Apoptosis in Melanoma Induced with Raf Inhibition Cutaneous Oncology Program, Dana Farber Cancer Institute January, 2005
18. Novel Immune-Based Therapies for Malignant Melanoma University of Chieti, Italy January, 2005
19. Targeting the MAP Kinase Pathway in the Treatment of Malignant Melanoma Innovations and Challenges in Melanoma Symposium, Cambridge, MA January, 2005
20. Therapeutic Targets in Renal Cell Carcinoma Kidney Cancer: New Therapeutic Options Investigators Meeting, WashingtonDC January, 2004
21. Regulation of FLIP Expression in Tumor and Endothelial Cells Grand Rounds, Division of Hematology-Oncology, BethIsraelDeaconessMedicalCenter January, 2003
22. Pharmacologic Regulation of Tumor Cell Susceptibility to Apoptosis 11th SPORE Workshop, Baltimore, MD January, 2003
23. A Review of Clinical Trials Conducted by the Cytokine Working Group (CWG) Zymogenetics, Seattle, WA January, 2002
24. Regulation of FLIP Expression in Tumor Cells Division of Hematology-Oncology, MassachusettsGeneralHospital January, 2001
25. Regulation of FLIP Expression in Tumor Cells National Institutes of Health January, 2001
26. Genetically Modified Salmonella typhimurium in the Treatment of Disseminated Malignancy Second Symposium on Advances in the Biology and Treatment of Cutaneous Melanoma, Boston, MA January, 2001
27. Regulation of FLIP Expression in Tumor Cells Roswell Park Memorial Institute, Buffalo, NY January, 2000
28. Regulation of FLIP Expression in Tumor Cells International Society for Interferon and Cytokine Research, Cleveland, Ohio January, 2000
29. HDM2 as a Therapeutic Target in Melanoma and Renal Cell Carcinoma Angiogenesis, Infiltration, and Metastasis (AIM) Program, Boston Children’s Hospital January, 2000
30. Vaccines and Mechanisms of Escape Society for Biologic Therapy, San Diego, CA (session co-chairman) January, 2000
31. Mechanisms of Tumor Escape from Immune Surveillance International Society for Biologic Therapy, San Francisco, CA January, 2000
32. Cancer Angiogenesis and Mechanism of Resistance to VEGF Inhibitors Cancer Biology Program, BethIsraelDeaconessMedicalCenter January, 2000
33. Mechanism of Apoptosis Induction in Melanoma Cells by BAY 43-9006 Bayer Pharmaceuticals, West Haven, CT January, 2000
34. Immune Dysfunction: Is it a Clinically Relevant Concept? The Fourth International Kidney Cancer Symposium, Chicago, IL January, 2000
35. GSK-3β Inhibition Enhances Sorafenib-Induced Apoptosis in Melanoma Cell Lines Fourteenth SPORE Workshop, Baltimore, MD January, 2000
36. Mechanism of Sorafenib-Induced Apoptosis in Melanoma Cells Cancer Biology Program, BethIsraelDeaconessMedicalCenter January, 2000
37. Therapy of Metastatic Renal Cell Carcinoma Division of Oncology, MaineMedicalCenter, Portland, ME January, 2000
38. Therapy of Renal Cell Carcinoma with Sutent: Mechanism of Acquired Resistance National Comprehensive Cancer Network Sunitinib Preclinical Studies Annual Investigators Meeting, WashingtonDC January, 2000
39. Angiogenesis and Immune Escape 2nd Annual Expert Forum on Malignant Melanoma, Santa Monica, CA January, 2000



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Best of Journals session: Renal Cancer Genitourinary Cancers Symposium February, 2014

Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.